[
  {
    "ts": "2025-12-19T14:50:50+00:00",
    "headline": "Merck (MRK)’s CEO Has a “Better Hand,” Says Jim Cramer",
    "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radar. Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical companies in the world. Its shares are flat year-to-date and would have been lower had it not been for a run […]",
    "url": "https://finance.yahoo.com/news/merck-mrk-ceo-better-hand-145050125.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "58531d84-3022-30e7-a752-ebc0e29c009a",
      "content": {
        "id": "58531d84-3022-30e7-a752-ebc0e29c009a",
        "contentType": "STORY",
        "title": "Merck (MRK)’s CEO Has a “Better Hand,” Says Jim Cramer",
        "description": "",
        "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radar. Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical companies in the world. Its shares are flat year-to-date and would have been lower had it not been for a run […]",
        "pubDate": "2025-12-19T14:50:50Z",
        "displayTime": "2025-12-19T14:50:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436",
          "originalWidth": 1280,
          "originalHeight": 853,
          "caption": "Merck (MRK)'s CEO Has a \"Better Hand,\" Says Jim Cramer",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tXp3W2zDkWcbYHYM_edP3Q--~B/aD04NTM7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436.cf.webp",
              "width": 1280,
              "height": 853,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BuRra1_S02PEU8kqjSl2RA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-ceo-better-hand-145050125.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-ceo-better-hand-145050125.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T14:50:22+00:00",
    "headline": "Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs",
    "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-couldn-t-stop-145022789.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ab2a1f66-2aed-3a18-891f-47fc1234232a",
      "content": {
        "id": "ab2a1f66-2aed-3a18-891f-47fc1234232a",
        "contentType": "STORY",
        "title": "Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs",
        "description": "",
        "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]",
        "pubDate": "2025-12-19T14:50:22Z",
        "displayTime": "2025-12-19T14:50:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53",
          "originalWidth": 1000,
          "originalHeight": 668,
          "caption": "Jim Cramer Couldn't Stop Gushing About Johnson & Johnson (JNJ)'s Cancer Drugs",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.1i2Xg8sqkYBwxzkIAC02w--~B/aD02Njg7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53.cf.webp",
              "width": 1000,
              "height": 668,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MUHt2SWlA2SDsXLMEXhTeg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-couldn-t-stop-145022789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-couldn-t-stop-145022789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T12:00:00+00:00",
    "headline": "Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2",
    "summary": "MSD declines to exercise option for EVX-B2 developmentEvaxion is now able to out-license EVX-B2 to another partnerEvaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studiesThere is no impact on Evaxion’s cash runway which extends to the second half of 2027 COPENHAGEN, Denmark, December 19, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has bee",
    "url": "https://finance.yahoo.com/news/evaxion-provides-msd-collaboration-retains-120000702.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c9988373-b81e-3556-8458-1c353df589b1",
      "content": {
        "id": "c9988373-b81e-3556-8458-1c353df589b1",
        "contentType": "STORY",
        "title": "Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2",
        "description": "",
        "summary": "MSD declines to exercise option for EVX-B2 developmentEvaxion is now able to out-license EVX-B2 to another partnerEvaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studiesThere is no impact on Evaxion’s cash runway which extends to the second half of 2027 COPENHAGEN, Denmark, December 19, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has bee",
        "pubDate": "2025-12-19T12:00:00Z",
        "displayTime": "2025-12-19T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/c9e7552492c4f1a24fb1488cbbdf90ad",
          "originalWidth": 4725,
          "originalHeight": 817,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tYvDc7gSSomQ_rmzZaDHww--~B/aD04MTc7dz00NzI1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c9e7552492c4f1a24fb1488cbbdf90ad.cf.webp",
              "width": 4725,
              "height": 817,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lmeAUk7TMhcgYja38s300g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c9e7552492c4f1a24fb1488cbbdf90ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/evaxion-provides-msd-collaboration-retains-120000702.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/evaxion-provides-msd-collaboration-retains-120000702.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EVAX"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T00:25:00+00:00",
    "headline": "Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes",
    "summary": "ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced the closing of a $20 million Series A financing. Proceeds will be used to advance the company’s lead program into Phase 2 clinical development for obesity and diabetes, as well as other programs in IND-enabling stage and early preclinical stage. The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital. “This Seri",
    "url": "https://finance.yahoo.com/news/rezubio-announces-20-million-series-002500188.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "94668ee9-f0b1-3aa3-be4d-a163c5d1562f",
      "content": {
        "id": "94668ee9-f0b1-3aa3-be4d-a163c5d1562f",
        "contentType": "STORY",
        "title": "Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes",
        "description": "",
        "summary": "ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced the closing of a $20 million Series A financing. Proceeds will be used to advance the company’s lead program into Phase 2 clinical development for obesity and diabetes, as well as other programs in IND-enabling stage and early preclinical stage. The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital. “This Seri",
        "pubDate": "2025-12-19T00:25:00Z",
        "displayTime": "2025-12-19T00:25:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/5b7bc3c9378a06f0f9e818ac3da0ba8b",
          "originalWidth": 1045,
          "originalHeight": 322,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_bnmPzEePccFogARfcqd4g--~B/aD0zMjI7dz0xMDQ1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5b7bc3c9378a06f0f9e818ac3da0ba8b.cf.webp",
              "width": 1045,
              "height": 322,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e.sacMMI1CJ4arMD2IHhxQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5b7bc3c9378a06f0f9e818ac3da0ba8b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rezubio-announces-20-million-series-002500188.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rezubio-announces-20-million-series-002500188.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T14:45:04+00:00",
    "headline": "Here's Why Merck (MRK) is a Strong Growth Stock",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finance.yahoo.com/news/heres-why-merck-mrk-strong-144504838.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "cbd340b2-e95b-3e36-9d10-9ab0e1a122a1",
      "content": {
        "id": "cbd340b2-e95b-3e36-9d10-9ab0e1a122a1",
        "contentType": "STORY",
        "title": "Here's Why Merck (MRK) is a Strong Growth Stock",
        "description": "",
        "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
        "pubDate": "2025-12-19T14:45:04Z",
        "displayTime": "2025-12-19T14:45:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b",
          "originalWidth": 900,
          "originalHeight": 711,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bjs59nqcRE8iEsudL3mMxA--~B/aD03MTE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 900,
              "height": 711,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bro_swiyYm6CQ_YbyBgC9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-merck-mrk-strong-144504838.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-merck-mrk-strong-144504838.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T11:01:21+00:00",
    "headline": "Novo files for CagriSema approval; Merck and Pfizer’s trial win",
    "summary": "Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer trial",
    "url": "https://www.biopharmadive.com/news/novo-cagrisema-merck-pfizer-keytruda-padcev-gsk/808142/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "381d876d-019f-355f-95ed-426d2c5d943c",
      "content": {
        "id": "381d876d-019f-355f-95ed-426d2c5d943c",
        "contentType": "STORY",
        "title": "Novo files for CagriSema approval; Merck and Pfizer’s trial win",
        "description": "",
        "summary": "Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer trial",
        "pubDate": "2025-12-19T11:01:21Z",
        "displayTime": "2025-12-19T11:01:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/novo-cagrisema-merck-pfizer-keytruda-padcev-gsk/808142/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-files-cagrisema-approval-merck-110121453.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CAMP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T19:44:47+00:00",
    "headline": "Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump",
    "summary": "Dow Jones stock Merck struck a Most Favored Nation agreement with the Trump administration on Friday, joining other pharma bellwethers.",
    "url": "https://www.investors.com/news/technology/merck-most-favored-nation-drug-pricing-deal/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "2cb395b6-a638-3e88-a9aa-fb560f3deaa3",
      "content": {
        "id": "2cb395b6-a638-3e88-a9aa-fb560f3deaa3",
        "contentType": "STORY",
        "title": "Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump",
        "description": "",
        "summary": "Dow Jones stock Merck struck a Most Favored Nation agreement with the Trump administration on Friday, joining other pharma bellwethers.",
        "pubDate": "2025-12-19T19:44:47Z",
        "displayTime": "2025-12-19T19:44:47Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/2cb395b6-a638-3e88-a9aa-fb560f3deaa3/dow-jones-merck-other.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/3a897c85d50513809da70438e2285a69",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J52TnzuAhPRkxQcQYwjwUg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/3a897c85d50513809da70438e2285a69.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Jcx0qKVoS.mXc1N2ud7p5Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/3a897c85d50513809da70438e2285a69.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/merck-most-favored-nation-drug-pricing-deal/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T19:39:00+00:00",
    "headline": "Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans",
    "summary": "RAHWAY, N.J., December 19, 2025--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans",
    "url": "https://finance.yahoo.com/news/merck-reaches-agreement-u-government-193900407.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "5923ba0c-e334-3285-8720-1c863795f995",
      "content": {
        "id": "5923ba0c-e334-3285-8720-1c863795f995",
        "contentType": "STORY",
        "title": "Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans",
        "description": "",
        "summary": "RAHWAY, N.J., December 19, 2025--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans",
        "pubDate": "2025-12-19T19:39:00Z",
        "displayTime": "2025-12-19T19:39:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/0cf4e6d27855490aa97643bdad47d2a8",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fqqxwlY0oD4ryr6bz3lAfw--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0cf4e6d27855490aa97643bdad47d2a8.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/shwP_unodM3Yhqxub.lxwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0cf4e6d27855490aa97643bdad47d2a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-reaches-agreement-u-government-193900407.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-reaches-agreement-u-government-193900407.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T17:31:55+00:00",
    "headline": "Three Prominent Dividend Stocks To Consider",
    "summary": "As the U.S. stock market experiences a resurgence, with major indexes like the Nasdaq and S&P 500 seeing notable gains driven by tech shares, investors are keenly observing opportunities across various sectors. In this dynamic environment, dividend stocks stand out as a compelling option for those seeking consistent income streams alongside potential capital appreciation.",
    "url": "https://finance.yahoo.com/news/three-prominent-dividend-stocks-consider-173155975.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "066ab4b2-acb3-39fc-99fc-fcac29994def",
      "content": {
        "id": "066ab4b2-acb3-39fc-99fc-fcac29994def",
        "contentType": "STORY",
        "title": "Three Prominent Dividend Stocks To Consider",
        "description": "",
        "summary": "As the U.S. stock market experiences a resurgence, with major indexes like the Nasdaq and S&P 500 seeing notable gains driven by tech shares, investors are keenly observing opportunities across various sectors. In this dynamic environment, dividend stocks stand out as a compelling option for those seeking consistent income streams alongside potential capital appreciation.",
        "pubDate": "2025-12-19T17:31:55Z",
        "displayTime": "2025-12-19T17:31:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/75a6275a0d81fd5fbc47ebecee672e4c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GtOHmHb7ARVdAFXcUOUznw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/75a6275a0d81fd5fbc47ebecee672e4c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CbeCLvAoO9qtHaSiLUwLfg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/75a6275a0d81fd5fbc47ebecee672e4c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/three-prominent-dividend-stocks-consider-173155975.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/three-prominent-dividend-stocks-consider-173155975.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "FRME"
            },
            {
              "symbol": "FRMEP"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "INDB"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "PFS"
            },
            {
              "symbol": "PEBO"
            },
            {
              "symbol": "OTCM"
            },
            {
              "symbol": "HST"
            },
            {
              "symbol": "FIBK"
            },
            {
              "symbol": "FMNB"
            },
            {
              "symbol": "EBF"
            },
            {
              "symbol": "DDS"
            },
            {
              "symbol": "COLB"
            },
            {
              "symbol": "CZNC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T17:15:00+00:00",
    "headline": "Pharma's $370B Bet on America: The ETF Plays for 2026",
    "summary": "Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.",
    "url": "https://finance.yahoo.com/news/pharmas-370b-bet-america-etf-171500181.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "33fcaabd-c7f4-3fb2-94b5-2bcf58713c2e",
      "content": {
        "id": "33fcaabd-c7f4-3fb2-94b5-2bcf58713c2e",
        "contentType": "STORY",
        "title": "Pharma's $370B Bet on America: The ETF Plays for 2026",
        "description": "",
        "summary": "Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.",
        "pubDate": "2025-12-19T17:15:00Z",
        "displayTime": "2025-12-19T17:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZemfjVvYBRw3W8.nEBguuA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wNN8n2_YU3n6CER2COkU_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pharmas-370b-bet-america-etf-171500181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharmas-370b-bet-america-etf-171500181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "IHE"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "NVSEF"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PJP"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "PPH"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T16:48:33+00:00",
    "headline": "Top Midday Stories: Oracle, Others Form JV to Oversee TikTok in US; More Drugmakers to Announce US Drug Price Deals",
    "summary": "All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige",
    "url": "https://finance.yahoo.com/news/top-midday-stories-oracle-others-164833427.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "1761f90c-fb96-3c96-96e0-69080592861e",
      "content": {
        "id": "1761f90c-fb96-3c96-96e0-69080592861e",
        "contentType": "STORY",
        "title": "Top Midday Stories: Oracle, Others Form JV to Oversee TikTok in US; More Drugmakers to Announce US Drug Price Deals",
        "description": "",
        "summary": "All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige",
        "pubDate": "2025-12-19T16:48:33Z",
        "displayTime": "2025-12-19T16:48:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-midday-stories-oracle-others-164833427.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-midday-stories-oracle-others-164833427.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ORCL"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "FOLD"
            },
            {
              "symbol": "BMRN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T15:32:00+00:00",
    "headline": "Can Merck Successfully Steer Through the Upcoming Headwinds?",
    "summary": "MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.",
    "url": "https://finance.yahoo.com/news/merck-successfully-steer-upcoming-headwinds-153200933.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6b05d209-9756-31cc-b401-e6f59b677ca5",
      "content": {
        "id": "6b05d209-9756-31cc-b401-e6f59b677ca5",
        "contentType": "STORY",
        "title": "Can Merck Successfully Steer Through the Upcoming Headwinds?",
        "description": "",
        "summary": "MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.",
        "pubDate": "2025-12-19T15:32:00Z",
        "displayTime": "2025-12-19T15:32:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RRg0vYpNavphT7S8O9jT7w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hIkvgr9e5vaptAEV_vkcVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-successfully-steer-upcoming-headwinds-153200933.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-successfully-steer-upcoming-headwinds-153200933.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T21:09:45+00:00",
    "headline": "Nine Drugmakers Strike Deals With Trump, With More to Come",
    "summary": "The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad.  “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.",
    "url": "https://finance.yahoo.com/news/nine-drugmakers-strike-deals-trump-193259194.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "4b465f35-8d3c-3995-a661-e4cd7f05b432",
      "content": {
        "id": "4b465f35-8d3c-3995-a661-e4cd7f05b432",
        "contentType": "STORY",
        "title": "Nine Drugmakers Strike Deals With Trump, With More to Come",
        "description": "",
        "summary": "The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad.  “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.",
        "pubDate": "2025-12-19T21:09:45Z",
        "displayTime": "2025-12-19T21:09:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/0ea477c2d30cc141387bcde902150c0a",
          "originalWidth": 2000,
          "originalHeight": 1333,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yPpId7n3nm6_XRF64S8wVg--~B/aD0xMzMzO3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/0ea477c2d30cc141387bcde902150c0a.cf.webp",
              "width": 2000,
              "height": 1333,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PHjfupuwaI2I5LGARA8SaA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/0ea477c2d30cc141387bcde902150c0a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nine-drugmakers-strike-deals-trump-193259194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nine-drugmakers-strike-deals-trump-193259194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T20:58:15+00:00",
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks rose late Friday afternoon, with the NYSE Health Care Index increasing 0.8% and t",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-205815703.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "8a5f8e8c-2979-3519-a99f-ac38fda65309",
      "content": {
        "id": "8a5f8e8c-2979-3519-a99f-ac38fda65309",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Rise Late Afternoon",
        "description": "",
        "summary": "Health care stocks rose late Friday afternoon, with the NYSE Health Care Index increasing 0.8% and t",
        "pubDate": "2025-12-19T20:58:15Z",
        "displayTime": "2025-12-19T20:58:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-205815703.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-205815703.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "XLV"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "FOLD"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "BMRN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T20:20:00+00:00",
    "headline": "Better Buy in 2026: Pfizer or Merck?",
    "summary": "This year has been one to forget for these pharmaceutical giants.",
    "url": "https://www.fool.com/investing/2025/12/19/better-buy-in-2026-pfizer-or-merck/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "978cc8b4-eda2-3a44-8084-5105e28e1bc9",
      "content": {
        "id": "978cc8b4-eda2-3a44-8084-5105e28e1bc9",
        "contentType": "STORY",
        "title": "Better Buy in 2026: Pfizer or Merck?",
        "description": "",
        "summary": "This year has been one to forget for these pharmaceutical giants.",
        "pubDate": "2025-12-19T20:20:00Z",
        "displayTime": "2025-12-19T20:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/4cc173b17304113970d31d379090c2b8",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Doctor talking to patient.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/awC9dwGn1n510BXC1DLdVg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/4cc173b17304113970d31d379090c2b8.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Fvj30fbjn7rtka8FSKyCtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4cc173b17304113970d31d379090c2b8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/19/better-buy-in-2026-pfizer-or-merck/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/better-buy-2026-pfizer-merck-202000176.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T20:14:09+00:00",
    "headline": "Jim Cramer Explains How Market Rotation Boosted Companies Like Johnson & Johnson",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer talked about recently. Cramer mentioned the stock during the episode and said: “These groups were the salvation of this market when the year of magical investing ended, and the super speculative stocks started coming back to earth, they’re still doing it, followed by the […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-explains-market-rotation-201409602.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "af2a6edf-afa8-352b-852d-b1a11a0c4ddc",
      "content": {
        "id": "af2a6edf-afa8-352b-852d-b1a11a0c4ddc",
        "contentType": "STORY",
        "title": "Jim Cramer Explains How Market Rotation Boosted Companies Like Johnson & Johnson",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer talked about recently. Cramer mentioned the stock during the episode and said: “These groups were the salvation of this market when the year of magical investing ended, and the super speculative stocks started coming back to earth, they’re still doing it, followed by the […]",
        "pubDate": "2025-12-19T20:14:09Z",
        "displayTime": "2025-12-19T20:14:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/e7ce02738b547dc513a8196cdef40274",
          "originalWidth": 3000,
          "originalHeight": 2001,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zgGnN5_Eo43a8q_OlIjzcw--~B/aD0yMDAxO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/e7ce02738b547dc513a8196cdef40274.cf.webp",
              "width": 3000,
              "height": 2001,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kECo7pezzO059xwHgOx8rw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/e7ce02738b547dc513a8196cdef40274.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-explains-market-rotation-201409602.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-explains-market-rotation-201409602.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "META"
            },
            {
              "symbol": "MSFT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T19:50:35+00:00",
    "headline": "More Big Drugmakers Reach Pricing Deals With White House",
    "summary": "Nine pharmaceutical companies including Merck and GSK agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration.  The companies agreed to reduce U.S. prices on drugs to levels comparable with prices charged in other wealthy countries, which are generally much lower.  Merck, for example, said it would make diabetes drugs Januvia and Janumet available to eligible American patients at a cash price that is 70% off the current list price through a direct-to-patient program.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-12-19-2025/card/more-big-drugmakers-reach-pricing-deals-with-white-house-kGn1aUHVq7BEDO975ZVn?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "28759601-6a97-301b-a4c3-6d2e2639d7a5",
      "content": {
        "id": "28759601-6a97-301b-a4c3-6d2e2639d7a5",
        "contentType": "STORY",
        "title": "More Big Drugmakers Reach Pricing Deals With White House",
        "description": "",
        "summary": "Nine pharmaceutical companies including Merck and GSK agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration.  The companies agreed to reduce U.S. prices on drugs to levels comparable with prices charged in other wealthy countries, which are generally much lower.  Merck, for example, said it would make diabetes drugs Januvia and Janumet available to eligible American patients at a cash price that is 70% off the current list price through a direct-to-patient program.",
        "pubDate": "2025-12-19T19:50:35Z",
        "displayTime": "2025-12-19T19:50:35Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/28759601-6a97-301b-a4c3-6d2e2639d7a5/more-big-drugmakers-reach.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AC.ajdS9OghfMNW3mzlvpg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J5JxVR9DmLuomtxdXBS7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-12-19-2025/card/more-big-drugmakers-reach-pricing-deals-with-white-house-kGn1aUHVq7BEDO975ZVn?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T21:46:36+00:00",
    "headline": "Trump reaches deal with 9 drug companies to lower prices",
    "summary": "President Trump announced deals with nine major drug makers in a move to reduce pharmaceutical prices, granting a three-year break on trade tariffs if they invest more into US manufacturing. Market Domination Overtime host Jared Blikre breaks down the news. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Domination Overtime.",
    "url": "https://finance.yahoo.com/video/trump-reaches-deal-9-drug-214636774.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "9956223c-960c-345a-8146-9d2c9b93a57d",
      "content": {
        "id": "9956223c-960c-345a-8146-9d2c9b93a57d",
        "contentType": "VIDEO",
        "title": "Trump reaches deal with 9 drug companies to lower prices",
        "description": "<p>President Trump announced deals with nine major drug makers in a move to reduce pharmaceutical prices, granting a three-year break on trade tariffs if they invest more into US manufacturing. Market Domination Overtime host <a data-i13n=\"cpos:1;pos:1\" href=\"https://www.yahoo.com/author/jared-blikre/\">Jared Blikre</a> breaks down the news.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-domination-overtime/\">Market Domination Overtime</a>.</p>",
        "summary": "President Trump announced deals with nine major drug makers in a move to reduce pharmaceutical prices, granting a three-year break on trade tariffs if they invest more into US manufacturing. Market Domination Overtime host Jared Blikre breaks down the news. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Domination Overtime.",
        "pubDate": "2025-12-19T21:46:36Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-12/fbe7c630-dd23-11f0-be1b-ca8a827544f0",
          "originalWidth": 6000,
          "originalHeight": 3378,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/v0H6RhbApqR6gF9mnCNQyQ--~B/aD0zMzc4O3c9NjAwMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-12/fbe7c630-dd23-11f0-be1b-ca8a827544f0.cf.webp",
              "width": 6000,
              "height": 3378,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/idU6qGRTamtAEjYrvLeFRg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-12/fbe7c630-dd23-11f0-be1b-ca8a827544f0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/trump-reaches-deal-9-drug-214636774.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/trump-reaches-deal-9-drug-214636774.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "NVSEF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T19:50:35+00:00",
    "headline": "Nine Big Drugmakers Reach Pricing Deals With White House",
    "summary": "Nine pharmaceutical companies including Merck and GSK agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration.  The companies agreed to reduce U.S. prices on drugs to levels comparable with prices charged in other wealthy countries, which are generally much lower.  Merck, for example, said it would make diabetes drugs Januvia and Janumet available to eligible American patients at a cash price that is 70% off the current list price through a direct-to-patient program.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-12-19-2025/card/more-big-drugmakers-reach-pricing-deals-with-white-house-kGn1aUHVq7BEDO975ZVn?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "28759601-6a97-301b-a4c3-6d2e2639d7a5",
      "content": {
        "id": "28759601-6a97-301b-a4c3-6d2e2639d7a5",
        "contentType": "STORY",
        "title": "Nine Big Drugmakers Reach Pricing Deals With White House",
        "description": "",
        "summary": "Nine pharmaceutical companies including Merck and GSK agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration.  The companies agreed to reduce U.S. prices on drugs to levels comparable with prices charged in other wealthy countries, which are generally much lower.  Merck, for example, said it would make diabetes drugs Januvia and Janumet available to eligible American patients at a cash price that is 70% off the current list price through a direct-to-patient program.",
        "pubDate": "2025-12-19T19:50:35Z",
        "displayTime": "2025-12-19T19:50:35Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/28759601-6a97-301b-a4c3-6d2e2639d7a5/nine-big-drugmakers-reach.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/cf87c53b3cccc20f45c8000006fc49aa",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fUvguSL7mQo4dXpEX6T9aw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/cf87c53b3cccc20f45c8000006fc49aa.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eAdcQEKH_hFqWp7XUNyo5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/cf87c53b3cccc20f45c8000006fc49aa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-12-19-2025/card/more-big-drugmakers-reach-pricing-deals-with-white-house-kGn1aUHVq7BEDO975ZVn?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T22:02:00+00:00",
    "headline": "Top Research Reports for NVIDIA, Netflix & Merck",
    "summary": "New research highlights NVIDIA's AI-driven growth, Netflix's ad-tier momentum and Merck's pipeline progress, while microcaps also make the cut.",
    "url": "https://finance.yahoo.com/news/top-research-reports-nvidia-netflix-220200828.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "de0689be-614c-3e71-a0dd-5b378f805cdd",
      "content": {
        "id": "de0689be-614c-3e71-a0dd-5b378f805cdd",
        "contentType": "STORY",
        "title": "Top Research Reports for NVIDIA, Netflix & Merck",
        "description": "",
        "summary": "New research highlights NVIDIA's AI-driven growth, Netflix's ad-tier momentum and Merck's pipeline progress, while microcaps also make the cut.",
        "pubDate": "2025-12-19T22:02:00Z",
        "displayTime": "2025-12-19T22:02:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-research-reports-nvidia-netflix-220200828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-research-reports-nvidia-netflix-220200828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "MDT"
            },
            {
              "symbol": "UBS"
            },
            {
              "symbol": "SCCO"
            },
            {
              "symbol": "NFLX"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "MCEM"
            },
            {
              "symbol": "CPIX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]